Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Lorem ipsum dolor
dolor sit amet
consectetur adipiscing elit.
Lorem ipsum dolor
dolor sit amet
consectetur adipiscing elit.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam scelerisque justo urna, vitae sagittis enim feugiat id. Cras dapibus erat in orci aliquam, placerat consectetur elit viverra. Nunc vulputate magna sit amet nisl tincidunt, pretium molestie erat aliquet. Suspendisse consectetur tempus urna, vitae laoreet dui.
Meet Our Team.
Meet Our Team.
Our team brings together scientific expertise, commercial experience and strategic leadership, united by a shared commitment to advancing VascVersa’s platform and its potential impact in vascular biology and cell therapy.
Dr Timothy Allsopp
Chief Technical Officer
Tim has over 20 years' experience in the advanced therapies sector, managing discovery to innovation and innovation into clinical development. As an investor in Vascversa, he is a board observer providing key strategic advice to support the development of the company's strategy for commercialization of Vascversa’s platform. He is also the founder and managing director of Consilium Bio Ltd, a specialist life science consultancy.
Aidan Courtney
Chairman
Aidan has over 20 years’ experience building life science and technology businesses. He co-founded and served as CEO of Roslin Cells, growing it to 70 staff and leading its work in cell therapy manufacturing and drug discovery services. He later became CEO of Censo Biotechnologies and now holds executive, non-executive and advisory roles with a number of early-stage technology companies in the sector.
Professor Alan Stitt
Co-founder
Professor Stitt is Dean of Innovation and Impact at Queen’s University Belfast’s School of Medicine, Dentistry and Biomedical Sciences. He has over 30 years’ experience in vascular biology and is internationally recognised for his work in retinal vascular diseases. A member of the Royal Irish Academy, he advises VascVersa through his expertise in diabetes, vascular biology and academic collaboration.
Dr Christina O’Neill
Co-founder
Dr Christina O’Neill is CEO of VascVersa and has over a decade’s experience in vascular biology as a postdoctoral scientist at Queen’s University Belfast. She pioneered work isolating the vascular stem cells behind ANGICYTE™ technology and has helped optimise their production. She has led key funding and commercialisation programmes, combining scientific expertise with strong business leadership.
Prof Reinhold Medina
Co-founder
Professor Medina is a Research Group Leader at Queen’s University Belfast. He holds an MD from Peru and a PhD in Stem Cell Biology from Japan. Internationally recognised in vascular stem cell biology, with over 3,000 citations, he is committed to translational medicine and cell therapy. He advises VascVersa with scientific expertise in vascular stem cell biology and its clinical application.